Axogen develops and markets regenerative medicine products for peripheral nerve repair. Its portfolio includes processed nerve allografts such as Avance Nerve Graft, nerve connectors, wraps and related tools used by surgeons to reconstruct damaged or severed nerves. The company serves trauma, reconstructive and oral-maxillofacial surgical markets where standard sutures alone are often insufficient for meaningful nerve recovery.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 56.7 | — | 0.6 | — |
| Q3 2025 | 60.1 | — | 0.7 | — |
| Q4 2025 | 59.9 | — | -13.2 | — |
| Q1 2026 | 61.5 | — | -19.6 | — |
| Q2 2026 | 69.7 | 23.1% | -1.5 | -361.8% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: EZCORP, Inc. (EZPW), Fermi Inc. (FRMI), The Bancorp, Inc. (TBBK), Polibeli Group Ltd (PLBL), SELLAS Life Sciences Group, Inc. (SLS), Vera Therapeutics, Inc. (VERA)